From: Is reducing variability of blood glucose the real but hidden target of intensive insulin therapy?
 | Glycemic control, mmol/La | Insulin protocol application | Mortality |  | |||
---|---|---|---|---|---|---|---|
 | Conventional | IIT | Conventional | IIT | Conventional | IIT | P value |
Leuven I trial [7] | 8.5 ± 1.8 | 5.7 ± 1.1 | 307/783 (39.2%) | 755/765 (98.7%) | 63/783 (8.0%) | 35/765 (4.6%) | <0.04 |
Leuven II trial [8] | 8.5 ± 1.7 | 6.2 ± 1.6 | 426/605 <0.04 | 580/595 (98%) | 162/605 (26.8%) | 144/595 (24.2%) | 0.31 |
VISEP study [13] | 8.4 ± 1.8 | 6.2 ± 1.0 | 215/290 (74.1%) | 243/247 (98.4%) | 75/289 (26.0%) | 61/247 (24.7%) | 0.74 |